0001171000-15-000110.txt : 20151124
0001171000-15-000110.hdr.sgml : 20151124
20151124155715
ACCESSION NUMBER: 0001171000-15-000110
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151123
FILED AS OF DATE: 20151124
DATE AS OF CHANGE: 20151124
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GEARING DAVID
CENTRAL INDEX KEY: 0001632481
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 151252655
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-11-23
0001618561
Nexvet Biopharma plc
NVET
0001632481
GEARING DAVID
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK,RAHAN ROAD
TULLAMORE , CO. OFFALY
L2
R35 FR98
IRELAND
0
1
0
0
Chief Scientific Officer
Ordinary Shares
2015-11-23
4
M
0
5600
.125
A
279330
I
By Gearing Family Pty Ltd <Gearing Family A/C>
Ordinary Shares
5600
D
Ordinary Shares
83664
I
By DJGearing Pty Ltd <Gearing Family Superannuation Fund A/C>
Options to purchase shares
.125
2015-11-23
4
M
0
5600
0
D
2019-07-01
Ordinary Shares
5600
7466
I
By Gearing Family Pty Ltd <Gearing Family A/C>
The reporting person and his spouse have shared voting and dispositive power with respect to these reported securities.
5,600 options to purchase shares vested and became exercisable on 11/19/15 after the Issuer's board of directors determined that there had been successful completion of an efficacy trial for an Issuer product. A further 3,733 options will vest and be exercisable on each of 7/1/16 and 1/1/17.
/s/ David Gearing by Geraldine T. Farrell, Attorney-in-Fact
2015-11-23